Earnings summaries and quarterly performance for BridgeBio Oncology Therapeutics.
Research analysts covering BridgeBio Oncology Therapeutics.
Recent press releases and 8-K filings for BBOT.
BridgeBio Oncology Therapeutics Updates Clinical Pipeline Data
BBOT
New Projects/Investments
- BridgeBio Oncology Therapeutics (BBOT) provided a clinical data update on its three oncology programs: 8520, BBO-11818, and BBO-10203.
- 8520, a KRAS G12C on-off inhibitor, demonstrated a 65% overall response rate and 83% durability at six months in monotherapy, with a differentiated safety profile, and showed an early signal of 100% response rate in STK11 KEAP1 co-mutations.
- BBO-11818, a pan-KRAS inhibitor, achieved a confirmed partial response in a heavily pretreated pancreatic patient, marking it as the first pan-KRAS inhibitor to do so.
- BBO-10203, a RAS PI3K alpha breaker, completed Phase 1 monotherapy with a differentiated safety profile, notably no hyperglycemia of any grade, and achieved a 62% disease control rate in heavily pretreated patients.
- BBOT plans to initiate combination studies of 8520 and 203 this year, followed by 818 and 203 later this year, to explore synergistic effects in KRAS mutant patients.
Jan 13, 2026, 1:15 AM
BridgeBio Oncology Therapeutics Provides Clinical Data Updates for Key Oncology Programs
BBOT
New Projects/Investments
- BridgeBio Oncology Therapeutics' BBOT-8520, a direct KRAS G12C on-off inhibitor, demonstrated a 65% overall response rate and 100% disease control rate in monotherapy for previously treated non-small cell lung cancer patients, with a differentiated safety profile including no grade three or higher liver toxicity.
- The company's pan-KRAS inhibitor, BBO-11818, showed a confirmed partial response in a heavily pretreated pancreatic patient during its Phase 1 dose escalation study.
- BBO-10203, a novel RAS PI3K alpha breaker, completed Phase 1 monotherapy objectives, identifying a recommended dose for expansion and exhibiting a differentiated safety profile with no hyperglycemia of any grade.
- BBOT plans to open combination cohorts for 8520 with 203 this year (2026), and 818 with 203 later this year (2026), aiming for synergistic effects in KRAS mutant patients.
Jan 13, 2026, 1:15 AM
BBOT Highlights Positive Clinical Data for Key Oncology Programs
BBOT
New Projects/Investments
- BBOT's 8520, a direct KRAS G12C inhibitor, demonstrated strong monotherapy efficacy with a 65% overall response rate and 100% disease control rate in previously treated non-small cell lung cancer patients, alongside a differentiated safety profile with no grade three or higher liver toxicity.
- 8520 also showed promising results in combination with pembrolizumab, maintaining its differentiated safety profile at fully active doses, and an early signal indicated all five STK11 KEAP1 co-mutated patients responded.
- The pan-KRAS inhibitor, BBO-11818, achieved a confirmed partial response with 56% tumor reduction in a heavily pretreated pancreatic patient.
- BBO-10203, a novel RAS PI3K alpha breaker, completed Phase 1 monotherapy with a differentiated safety profile, notably showing no hyperglycemia of any grade, and has opened all three combination cohorts with standard of care.
- BBOT plans to initiate combination studies of its internal assets, with 8520 and 203 combinations opening this year, and 818 and 203 combinations opening later this year.
Jan 13, 2026, 1:15 AM
BBOT Announces Positive Clinical Data for Oncology Pipeline
BBOT
New Projects/Investments
- BBOT is well-funded to support operations into 2028 and anticipates several meaningful value inflection points in 2026.
- The company's BBO-8520 monotherapy in KRAS G12C non-small cell lung cancer demonstrated a 65% overall response rate and 83% of patients with at least six-month follow-up remaining on treatment greater than six months, alongside a favorable safety profile.
- BBO-11818, a pan-KRAS inhibitor, showed anti-tumor activity, including a partial response in a pretreated pancreatic ductal adenocarcinoma patient.
- BBO-10203, a RAS PI3K alpha breaker, established a recommended dose of 500 milligrams QD for expansion studies, notably with no hyperglycemia observed.
- BBOT expects to announce updated data across all its programs in the second half of 2026.
Jan 7, 2026, 1:30 PM
BBOT Provides Clinical Data Update for RAS Pathway Inhibitors
BBOT
New Projects/Investments
- BridgeBio Oncology Therapeutics (BBOT) is well-funded to support operations into 2028.
- The company reported positive monotherapy data for BBO-8520, a KRAS G12C inhibitor, in non-small cell lung cancer patients, showing a 65% overall response rate and 83% of patients remaining on treatment for at least six months. This drug also demonstrated a favorable safety profile, particularly regarding liver enzyme elevations, and encouraging early efficacy signals in STK11 KEAP1 co-mutant tumors.
- BBO-11818, a pan-KRAS inhibitor, showed anti-tumor activity, including a partial response in a pretreated pancreatic ductal adenocarcinoma patient, with a favorable safety profile.
- BBO-10203, a RAS PI3K alpha breaker, achieved its monotherapy dose escalation objectives, establishing a recommended dose of 500 milligrams QD for expansion studies, notably with no hyperglycemia observed even without HbA1c restrictions.
Jan 7, 2026, 1:30 PM
BBOT Provides Update on Clinical Pipeline and Financial Outlook
BBOT
New Projects/Investments
Guidance Update
- BBOT maintains a strong balance sheet with a cash runway projected into 2028.
- The company's lead asset, BBO-8520, a dual KRASG12C ON and OFF inhibitor, demonstrated promising monotherapy data in NSCLC with a 65% Overall Response Rate (ORR) and 66% 6-month Progression-Free Survival (PFS), alongside a differentiated safety profile with no Grade 3 or higher liver toxicity.
- BBO-11818, a dual panKRAS ON and OFF inhibitor, showed anti-tumor activity, including a partial response in a pancreatic cancer patient, and a generally tolerable safety profile with no DLTs.
- BBO-10203, a novel RAS:PI3Kα Breaker, exhibited a potentially differentiated safety profile with no observed events of hyperglycemia and a monotherapy Disease Control Rate (DCR) of 62%.
- Multiple clinical assets, including BBO-8520, BBO-11818, and BBO-10203, have anticipated value inflection points in 2026, with additional efficacy and safety data expected in the second half of the year.
Jan 7, 2026, 1:30 PM
BridgeBio Oncology Therapeutics Announces Positive Clinical Data for Three Pipeline Programs
BBOT
New Projects/Investments
Product Launch
- BridgeBio Oncology Therapeutics, Inc. (BBOT) announced positive preliminary safety and antitumor data for its three orally bioavailable, differentiated small molecule RAS and PI3Kα programs: BBO-8520, BBO-11818, and BBO-10203.
- BBO-8520 monotherapy in patients with KRAS G12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with a favorable liver safety profile.
- BBO-11818 monotherapy demonstrated a partial response (PR) in pancreatic cancer with a 44% tumor reduction and generally favorable tolerability.
- BBO-10203 exhibited a potentially differentiated safety profile with no observed hyperglycemia, and combination studies with standard-of-care treatments in colorectal cancer and breast cancer have been initiated.
Jan 7, 2026, 12:09 PM
BridgeBio Oncology Highlights 2025 Accomplishments and Outlines 2026 Data Readouts
BBOT
New Projects/Investments
Guidance Update
M&A
- BridgeBio Oncology progressed all three of its in-house discovered oncology programs (BBO-8520, BBO-10203, and BBO-11818) into the clinic during 2025.
- The company successfully completed a de-SPAC merger in August 2025, raising approximately $380 million with 39% redemptions.
- Upcoming data readouts for all three programs are scheduled for 2026: BBO-8520 in Q1, BBO-10203 in 1H, and BBO-11818 in 2H.
- Early clinical data for BBO-8520 demonstrated a 60% confirmed overall response rate and a differentiated safety profile with no grade three toxicities or liver toxicity across initial dose escalation cohorts.
- Following the 2026 data readouts, BridgeBio Oncology plans a portfolio-wide evaluation and prioritization of its programs, considering strategic partnering for capital and execution needs.
Dec 3, 2025, 2:35 PM
BridgeBio Oncology Discusses 2025 Accomplishments and 2026 Clinical Data Readouts
BBOT
New Projects/Investments
Guidance Update
- BridgeBio Oncology progressed all three of its in-house discovered oncology programs (BBO-8520, BBO-11818, and BBO-10203) into the clinic in 2025.
- The company successfully went public in August 2025 through a de-SPAC process, raising approximately $380 million.
- Upcoming data readouts for all three programs are anticipated in 2026: BBO-8520 in Q1, BBO-10203 in H1, and BBO-11818 in H2.
- Early clinical data for BBO-8520 showed a 60% confirmed overall response rate and no Grade 3 toxicities across the first three dose escalation cohorts.
- The company plans a portfolio-wide evaluation and prioritization in the second half of 2026, after all data is available, and is open to strategic partnering for capital and executional capabilities.
Dec 3, 2025, 2:35 PM
BridgeBio Oncology Highlights 2025 Progress and Upcoming 2026 Clinical Milestones
BBOT
New Projects/Investments
M&A
Guidance Update
- BridgeBio Oncology completed its de-SPAC transaction in August 2025, raising approximately $380 million and providing financial runway for its clinical programs.
- The company advanced all three of its internally discovered oncology programs (8520, BBO-10203, and BBO-11818) into clinical development during 2025.
- Significant clinical data readouts are expected for all three programs in 2026: 8520 (G12C inhibitor) in Q1, BBO-10203 (PI3K alpha breaker) in H1, and BBO-11818 (pan-KRAS inhibitor) in H2.
- Initial clinical data for 8520 demonstrated a 60% confirmed overall response rate and a differentiated safety profile with no grade three toxicities or liver enzyme changes in monotherapy dose escalation.
- The company plans to prioritize its portfolio based on the 2026 data and is open to strategic partnerships to support the development of its programs.
Dec 3, 2025, 2:35 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more